ALK and neuroblastoma: It is known from experimental data that targetable mutations and alterations of oncogenic pathways in neuroblastoma are selected by chemotherapeutic agents and enriched at relapse [15]; examples are de novo mutations in ALK [16] and the genes encoding the RAS-MAPK pathway [17].